Management of Factor Xa inhibitor-associated life-threatening major hemorrhage: A retrospective multi-center analysis.

ABSTRACT:

Background

Factor Xa (FXa) inhibitors, used for stroke prevention in atrial fibrillation and venous thromboembolism treatment and prevention, are the dominant non-Vitamin K oral anticoagulants on the market. While major bleeding may be less common with these agents compared to warfarin, it is always a risk, and little has been published on the most serious bleeding scenarios. This study describes a cohort of patients with FXa inhibitor-associated life-threatening bleeding events, their clinical characteristics, interventions and outcomes.

Methods

We performed a retrospective, 5-center review of FXa inhibitor-treated major bleeding patients. Investigators identified potential cases by cross-referencing ICD-9/10 codes for hemorrhage with medication lists. Investigators selecte

SUBMITTER: Milling TJ 

PROVIDER: S-EPMC6049660 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature